Neurex, Warner-Lambert deal

NXCO received $3 million from Warner-Lambert, representing a $1.5 million equity investment and $1.5 million in advance royalty payments under a 1993 agreement to develop neuron specific calcium channel blockers for cardiorenal and neurological diseases. The transaction was triggered by NXCO's October offering of 3 million shares, which raised $13.5 million. ...